A detailed history of Price T Rowe Associates Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 16,603 shares of INZY stock, worth $48,646. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,603
Previous 16,370 1.42%
Holding current value
$48,646
Previous $74,000 17.57%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.31 - $6.0 $1,004 - $1,398
233 Added 1.42%
16,603 $87,000
Q2 2024

Aug 14, 2024

BUY
$4.33 - $7.31 $9,300 - $15,701
2,148 Added 15.1%
16,370 $74,000
Q1 2024

May 15, 2024

BUY
$4.14 - $7.66 $6,317 - $11,689
1,526 Added 12.02%
14,222 $109,000
Q4 2023

Feb 14, 2024

BUY
$2.71 - $4.5 $34,406 - $57,132
12,696 New
12,696 $55,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $118M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.